V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016940 | 160008407 | 1.57 | 67.8 | Neo-adjuvant (N) | 2018-12-23 | 2018-12-24 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 100527877 |
| 160016941 | 160008408 | 1.58 | 61.8 | Curative (C) | 2019-04-01 | 2019-04-01 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100856999 |
| 160016946 | 160008409 | 1.84 | 58 | 03 | 2016-10-04 | 2016-10-18 | PACLITAXEL | 2 | N | LIPOSOMAL DAUNORUBICIN | 100193304 |
| 160016947 | 160008410 | 1.53 | 79 | Palliative (P) | 2020-01-29 | 2020-02-11 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 100100243 |
| 160016948 | 160008411 | 1.72 | 184 | Neo-adjuvant (N) | null | 2017-05-13 | Bevacizumab 15mg/kg | N | null | EURO-EWING | 101428663 |
| 160016951 | 160008412 | 1.54 | 119.8 | Neo-adjuvant (N) | 2017-02-17 | 2017-03-09 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 101793839 |
| 160016952 | 160008413 | 1.82 | 67.7 | Palliative (P) | 2018-06-18 | 2018-07-02 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100773637 |
| 160016953 | 160008414 | 1.78 | 81.4 | Palliative (P) | 2016-01-30 | 2016-01-31 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100054016 |
| 160016955 | 160008415 | 1.89 | 81.1 | null | 2018-08-09 | 2018-08-09 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101863220 |
| 160016959 | 160008416 | 1.8 | 64 | null | 2019-05-15 | 2019-05-15 | Liposomal Doxorubicin 40mg/m2 | 02 | N | DOCETAXEL + GEMCITABINE | 100659204 |
| 160016962 | 160008417 | 1.69 | 64.5 | Curative (C) | 2019-04-21 | 2019-05-16 | Doxorubicin + Olaratumab | null | N | DOXORUBICIN + METHOTREXATE | 100095691 |
| 160016963 | 160008418 | 1.71 | 64 | Curative (C) | 2014-10-18 | 2017-10-04 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 101808076 |
| 160016964 | 160008419 | 1.64 | 59.6 | Palliative (P) | 2016-10-19 | 2016-11-02 | CARBOPLATIN | 02 | N | CARBOPLATIN | 101025781 |
| 160016965 | 160008420 | 1.6 | 87.3 | Palliative (P) | 2016-12-08 | 2016-12-08 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100019609 |
| 160016966 | 160008421 | 1.77 | 83.6 | 03 | 2018-12-10 | 2018-12-24 | ETOP 13-18 BEAT-meso Trial | 02 | N | CAV | 100083079 |
| 160016967 | 160008422 | 1.08 | 62.2 | Neo-adjuvant (N) | 2016-08-21 | 2016-08-30 | Carboplatin + Paclitaxel (3 weekly) | N | N | CARBOPLATIN + PACLITAXEL | 101201506 |
| 160016969 | 160008423 | 1.58 | 66 | Palliative (P) | 2019-03-25 | 2019-04-07 | Carboplatin + Paclitaxel (weekly) | N | N | CARBOPLATIN + PACLITAXEL | 100282628 |
| 160016971 | 160008424 | 1.62 | 77 | Palliative (P) | 2019-09-06 | 2019-09-08 | CARBOPLATIN | 02 | N | CARBOPLATIN | 100977599 |
| 160016975 | 160008425 | null | 75.65 | Palliative (P) | 2019-01-02 | 2019-01-05 | null | N | Y | CONFIRM TRIAL | 100761456 |
| 160016979 | 160008427 | 1.72 | 72 | Palliative (P) | null | 2018-09-10 | Ifosfamide + Liposomal Doxorubicin | N | N | IPILIMUMAB + NIVOLUMAB | 101266518 |
| 160016980 | 160008428 | 1.76 | 88 | null | null | 2017-04-10 | PACLITAXEL | N | N | DOXORUBICIN + OLARATUMAB | 101403988 |
| 160016981 | 160008429 | 1.74 | 77.3 | Palliative (P) | 2021-07-15 | 2021-07-19 | IPM | N | N | DOXORUBICIN + IFOSFAMIDE | 100550298 |
| 160016983 | 160008430 | 1.68 | null | Palliative (P) | 2020-02-23 | 2020-03-08 | Doxorubicin 75mg/m2 | 02 | null | DOXORUBICIN | 100518591 |
| 160016986 | 160008431 | 1.6 | 81.4 | Palliative (P) | 2018-03-31 | 2018-04-15 | DOXORUBICIN | N | N | NB LOW/INTERM RISK GUIDELINES CARBO/ETOP | 100200365 |
| 160016987 | 160008432 | 1.58 | 76.7 | Palliative (P) | null | 2021-01-26 | Doxorubicin 75mg/m2 | 02 | N | DOXORUBICIN | 100367732 |
| 160016988 | 160008433 | 1.7 | 68 | Curative (C) | 2018-12-14 | 2018-12-22 | null | 02 | N | NB LOW/INTERM RISK GUIDELINES CARBO/ETOP | 100910350 |
| 160016991 | 160008435 | 1.75 | 77.55 | Palliative (P) | 2014-02-08 | 2014-03-15 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101128729 |
| 160016993 | 160008436 | 1.7 | 60 | Palliative (P) | 2016-12-27 | 2016-12-28 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100212183 |
| 160016994 | 160008437 | 1.75 | 95.7 | Palliative (P) | 2016-10-18 | 2016-10-18 | PAM x 2 post-surgery (cycles 3&4) | 02 | N | CARBOPLATIN | 101183197 |
| 160016996 | 160008438 | 1.55 | 101.6 | Neo-adjuvant (N) | 2019-07-04 | 2019-07-05 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 100086284 |
| 160017000 | 160008439 | 1.56 | 83 | Palliative (P) | 2018-02-16 | 2018-02-28 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 101514865 |
| 160017002 | 160008440 | 1.79 | 69.7 | null | 2017-08-15 | 2017-08-28 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101119612 |
| 160017003 | 160008441 | 1.65 | 66 | Palliative (P) | 2016-12-28 | 2016-12-28 | Trial Unspecified | null | N | LIPOSOMAL DOXORUBICIN | 101497240 |
| 160017004 | 160008442 | null | null | 03 | 2019-04-30 | 2019-06-02 | Carboplatin AUC 2 - 5 | 02 | null | CARBOPLATIN | 101027973 |
| 160017008 | 160008443 | null | null | Neo-adjuvant (N) | 2019-07-25 | 2019-08-15 | Doxorubicin 75mg/m2 | 02 | null | DOXORUBICIN | 100090692 |
| 160017010 | 160008445 | 1.57 | 90.2 | Palliative (P) | 2015-07-11 | 2015-07-17 | Carboplatin AUC 6 - 10 | 01 | N | CARBOPLATIN | 100387630 |
| 160017011 | 160008446 | 1.7 | 58.5 | null | 2018-07-03 | 2018-07-04 | Doxorubicin 75mg/m2 | 02 | N | STS NON-RHABDO EPSSG 2005 | 100970885 |
| 160017018 | 160008448 | 1.88 | 76 | Palliative (P) | 2017-09-01 | 2017-09-02 | Doxorubicin + Ifosfamide | 2 | N | CISPLATIN + GEMCITABINE | 101215625 |
| 160017019 | 160008449 | 1.82 | 83 | Palliative (P) | 2018-02-16 | 2018-03-07 | Trial Unspecified | 02 | N | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 100745063 |
| 160017020 | 160008450 | 1.66 | 96 | Neo-adjuvant (N) | 2017-02-03 | 2017-02-03 | Doxorubicin 75mg/m2 | 02 | N | DOXORUBICIN | 101741365 |
| 160017023 | 160008451 | 1.63 | 107 | null | null | null | Doxorubicin + Olaratumab | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101140091 |
| 160017024 | 160008452 | 1.73 | 71.2 | Neo-adjuvant (N) | 2017-05-03 | 2017-05-03 | GC Int Guide Excranial GermCell JEB | 02 | Y | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 101513533 |
| 160017026 | 160008453 | null | null | Palliative (P) | 2018-05-20 | 2018-06-02 | Cisplatin + Pemetrexed | 02 | null | PACLITAXEL | 101054812 |
| 160017027 | 160008454 | 1.85 | 90.1 | Palliative (P) | null | 2017-03-28 | Cisplatin + Pemetrexed | 02 | Y | CISPLATIN + PEMETREXED | 101416533 |
| 160017029 | 160008455 | 1.65 | 113 | Curative (C) | 2018-09-19 | 2018-09-23 | CARBOPLATIN + PACLITAXEL | N | N | CARBOPLATIN + PACLITAXEL | 101001269 |
| 160017030 | 160008456 | 1.6 | 81.8 | Palliative (P) | 2017-08-06 | 2017-08-08 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 101823003 |
| 160017031 | 160008457 | 1.86 | 91 | null | 2019-04-16 | 2019-05-10 | Cisplatin + Pemetrexed | 02 | null | IPILIMUMAB + NIVOLUMAB | 100388956 |
| 160017032 | 160008458 | 1.74 | 78.65 | Curative (C) | 2017-03-19 | 2017-04-02 | DOXORUBICIN + IFOSFAMIDE | 02 | N | LIPOSOMAL DOXORUBICIN | 101275146 |
| 160017038 | 160008459 | 1.7 | 102.5 | Palliative (P) | 2017-10-02 | 2017-10-28 | Enzalutamide | 02 | N | DOXORUBICIN + OLARATUMAB | 100213662 |
| 160017040 | 160008460 | 1.55 | 58.1 | Curative (C) | 2016-03-17 | 2016-03-18 | Docetaxel + Gemcitabine with GCSF | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101521773 |